Long intergenic non‐coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo

Abstract

Background:This study aimed to investigate the correlation of long intergenic noncoding RNA 511 (LINC00511) with clinicopathological characteristics and overall survival (OS) in osteosarcoma patients and to explore its function in osteosarcoma in vitro and in vivo. Methods:Tumor tissues and adjacent tissues from 45 osteosarcoma patients were acquired, and LINC00511 expression was detected. In vitro, LINC00511 expression was detected in osteosarcoma cell lines and osteoblast cell line. LINC00511 overexpression-treated (OE-LINC00511) and nonsense overexpression-treated (OEcontrol) MG-63 and Saos-2 cells were cultured, followed by the assessment of cell proliferation, apoptosis, migration, and invasion. In vivo, tumor weight and volume were measured in OE-LINC00511 and OE-control xenografted mice.Results: LINC00511 expression was decreased in tumor tissues compared with adjacent tissues (P < .001), and its high expression correlated with increased tumor cell necrosis rate to neoadjuvant chemotherapy (P = .025) and prolonged OS (P = .010).In vitro, LINC00511 expression was decreased in osteosarcoma cell lines (including MG-63, U-2OS, Saos-2, and HOS) compared with osteoblast cell line (All P < .001).Cell proliferation was decreased at 48 hours (Both P < .01) and 72 hours (Both P < .001) (in MG-63 and Saos-2 cells); cell apoptosis was increased (P < .05) (in Saos-2 cells); cell migration and invasion were decreased (All P < .01) (in MG-63 cells and Saos-2 cells) in OE-LINC00511 compared with OE-control. In vivo, tumor volume was reduced at week 4 (P < .001), week 5 (P < .001), week 6 (P < .001) in OE-LINC00511 compared with OE-control. Tumor weight was declined in OE-LINC00511 than OEcontrol (P < .001). Conclusions: LINC00511 acts as a potential biomarker and therapeutic option for osteosarcoma.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.(HD-MTX) 10-12 g/m 2 intravenous drip within 5 hours, followed by intravenous injection of sodium folinate at 6 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 54 hours, 60 hours, 66 hours, and 72 hours (the complete of HD-MTX intravenous drip was defined as 0 hour), meanwhile, MTX concentration in plasma was monitored at 0 hour, 12 hours, 24 hours, 48 hours, and 72 hours; Day 8: adriamycin (ADM) 20 mg/m 2 /d × 3 days intravenous drip; Day 11: cisplatin (DDP) 120 mg/m 2 intravenous drip; Day 21: ifosfamide (IFO) 2 g/m 2 /d × 5 days intravenous drip, using Mesna to prevent hemorrhagic cystitis. Each cycle repeated every 3 weeks. A total of two cycles of IOR-OS/N-5 regimen were given to patients before surgery. When the neoadjuvant chemotherapy was completed, patients received amputation or limb-salvage surgery, which was decided with the consideration of patients' Ennecking stage, sensitivity to neoadjuvant chemotherapy, tu...

Prognostic significance of long intergenic non-protein-coding RNA 511expression in malignant tumors

“…Next, these 73 studies were carefully screened by the titles, abstracts, and full texts. Finally, a total of 13 eligible studies comprising 1053 cancer patients were included according to the inclusion and exclusion criteria in this meta-analysis [ 9 , 10 , 16 , 17 , 21 , 22 , 25 , 28 , 33 – 35 ] (Fig. 1 ).…”

“…[ 26 , 27 ] Nevertheless, some studies also reported that LINC00511 could be a tumor suppressor, with high LINC00511 expression being associated with favorable prognosis of some cancer patients. [ 28 ]…”

The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review

“…Long intergenic noncoding RNA 00511 (LINC00511) is a newly identified lncRNA and has been reported to be dysregulated in various malignant tumors, including glioma [7], ovarian cancer [8], breast cancer [9,10], cervical cancer [11,12], osteosarcoma [13], lung cancer [14], hepatocellular carcinoma [15][16][17], renal cell cancer [18], pancreatic cancer [19], gastric cancer [20][21][22], tongue squamous cell carcinoma [23] and papillary thyroid carcinoma [24]. To date, most literature suggested that LINC00511 was aberrantly upregulated in malignant tumors and its high expression correlated with poor survival of patients with glioma [7], ovarian cancer [8], breast cancer [9,10], cervical cancer [11,12], osteosarcoma [13], lung cancer [14], gastric cancer [22], hepatocellular carcinoma [15], renal cell cancer [18] or pancreatic cancer [19]. Furthermore, those studies revealed that LINC00511 could accelerate tumor progression by inhibiting malignant cell apoptosis and promoting tumor cell proliferation, migration, invasion, metastasis, chemotherapy resistance, and so on [10,11,17].…”

“…However, the association between LINC00511 expression and prognosis of patients with malignant tumor is still controversial. For example, Qiao et al [13] reported that LINC00511 was downregulated in osteosarcoma, which was related to improved survival. Additionally, they further demonstrated that upregulation of LINC00511 could impede the progression of osteosarcoma through inducing apoptosis and suppressing the migration and invasion of osteosarcoma cells [13].…”

“…For example, Qiao et al [13] reported that LINC00511 was downregulated in osteosarcoma, which was related to improved survival. Additionally, they further demonstrated that upregulation of LINC00511 could impede the progression of osteosarcoma through inducing apoptosis and suppressing the migration and invasion of osteosarcoma cells [13]. Moreover, the conclusions concerning the clinical role of LINC00511 expression in patients with malignancies in individual studies may be limited by small sample size.…”